Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | FDPS | P14324 | 9/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035850 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL5497688 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL8176550 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL5497444 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL1410606 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL424188 | 0.97 | FDPS (0.38) | GGPS1FDPSSMPD1CES2LPAR1 | |
| SCHEMBL1410618 | 0.90 | — | — | |
| SCHEMBL8906809 | 0.88 | FAAH (0.50) | — | |
| SCHEMBL10530613 | 0.81 | FDPS (0.30) | FDPS | |
| SCHEMBL7722417 | 0.80 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0662965-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1995-07-19 | — | — | EP | claimed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | claimed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | claimed |
| US-20150141460-A1 | Anti-inflammatory Compositions | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-20140336227-A1 | 3-AMINO LACTAMS AS ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-11-13 | — | — | US | disclosed |
| US-8853200-B2 | Treatment of rheumatoid arthritis with 3-amino lactam compounds | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-1896012-B1 | Anti-inflammatory agents | CAMBRIDGE ENTPR LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2572716-A1 | Anti-inflammatory Composition | Cambridge Enterprise Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| EP-2366391-A2 | Anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366390-A2 | Anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-20100324089-A1 | Anti-inflammatory composition | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-5321031-A | Treating cardiovascular disorders | SCHERING CORPORATION (US) | 1994-06-14 | — | — | US | disclosed |
| WO-1994006784-A1 | 1,2-DISUBSTITUTED ETHYL AMIDES AS INHIBITORS OF ACAT | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0583346-A1 | BICYCLIC AMIDES AS INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL ACYL TRANSFERASE | SCHERING CORPORATION (US) | 1994-02-23 | — | — | EP | disclosed |
| EP-0514851-A1 | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase | SCHERING CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| WO-1992018462-A1 | BICYCLIC AMIDES AS INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL ACYL TRANSFERASE | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0508425-A1 | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase | SCHERING CORPORATION (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5149709-A | Treatment of atherosclerosis | SCHERING CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
| US-5124337-A | Treating atherosclerosis | SCHERING CORPORATION (US) | 1992-06-23 | — | — | US | disclosed |
| US-4999379-A | Transdermal delivery of diclofenac | CIBA-GEIGY CORPORATION (US) | 1991-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336227-A1 | 3-AMINO LACTAMS AS ANTI-INFLAMMATORY AGENTS | IL1B, NFKBIA, IL1A | GGPS1 970/4885FDPS 2561/4885TSHR 4364/4885 |
| US-20150141460-A1 | Anti-inflammatory Compositions | TNF, PTGES2, IL1B | GGPS1 627/4885FDPS 491/4885TSHR 4856/4885 |
| US-20100324089-A1 | Anti-inflammatory composition | TNF, IL1B, IL1A | GGPS1 596/4885FDPS 547/4885TSHR 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.